May 15 |
Marker Therapeutics GAAP EPS of -$0.27 misses by $0.02, revenue of $1.24M
|
May 15 |
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
|
Apr 8 |
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
|
Mar 26 |
Marker Therapeutics GAAP EPS of -$1.59, revenue of $3.31M
|
Mar 25 |
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
|
Mar 22 |
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
Jan 22 |
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
|
Jan 8 |
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization
|
Jan 8 |
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
|